Go Pro

Extendicare (TSE:EXE) Price Target Raised to C$44.00 at Canaccord Genuity Group

Extendicare logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Canaccord Genuity raised Extendicare’s price target to C$44.00 from C$37.00 and maintained a “buy” rating, implying 36.69% potential upside.
  • Analyst sentiment remains positive, with one “strong buy” and seven “buy” ratings; the consensus price target is C$35.44.
  • Extendicare shares fell 0.8% to C$32.19 in mid-day trading. The company most recently reported quarterly EPS of C$0.32 on revenue of C$611.04 million.
  • Five stocks to consider instead of Extendicare.

Extendicare (TSE:EXE - Get Free Report) had its price target upped by investment analysts at Canaccord Genuity Group from C$37.00 to C$44.00 in a research note issued on Monday,BayStreet.CA reports. The firm presently has a "buy" rating on the stock. Canaccord Genuity Group's target price points to a potential upside of 36.69% from the stock's current price.

Several other research analysts have also recently issued reports on EXE. BMO Capital Markets lifted their target price on shares of Extendicare from C$30.00 to C$38.00 in a report on Wednesday, May 13th. TD boosted their price objective on shares of Extendicare from C$32.00 to C$39.00 and gave the stock a "buy" rating in a report on Monday, May 11th. National Bank Financial increased their target price on Extendicare from C$34.00 to C$40.00 and gave the company an "outperform" rating in a research note on Wednesday, May 27th. Finally, Desjardins lowered their target price on shares of Extendicare from C$40.00 to C$39.00 and set a "buy" rating on the stock in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. Based on data from MarketBeat, Extendicare has an average rating of "Buy" and a consensus price target of C$35.44.

Read Our Latest Research Report on EXE

Extendicare Stock Down 0.8%

Extendicare stock traded down C$0.25 during mid-day trading on Monday, hitting C$32.19. The company had a trading volume of 363,614 shares, compared to its average volume of 388,127. Extendicare has a 12 month low of C$12.64 and a 12 month high of C$39.14. The company has a market capitalization of C$3.05 billion, a PE ratio of 23.69 and a beta of 1.59. The stock's 50 day moving average price is C$35.24 and its two-hundred day moving average price is C$30.25. The company has a current ratio of 1.44, a quick ratio of 0.98 and a debt-to-equity ratio of 82.55.

Extendicare (TSE:EXE - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported C$0.32 earnings per share (EPS) for the quarter. The firm had revenue of C$611.04 million during the quarter. Extendicare had a return on equity of 45.35% and a net margin of 6.99%. As a group, sell-side analysts anticipate that Extendicare will post 0.6134729 earnings per share for the current fiscal year.

Extendicare Company Profile

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Further Reading

Analyst Recommendations for Extendicare (TSE:EXE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines